Table 1.
Participant Demographics and Baseline Characteristics
| Parameter | VT-1161 300 mg q.d. (n = 14) | VT-1161 600 mg q.d. (n = 12) | VT-1161 600 mg b.i.d. (n = 14) | Fluconazole 150 mg (n = 15) | Overall (N = 55) |
|---|---|---|---|---|---|
| Age (y) | 34.4 ± 12.01 | 38.2 ± 11.77 | 27.6 ± 7.37 | 31.3 ± 8.22 | 32.7 ± 10.40 |
| Race | |||||
| White | 7 (50.0) | 9 (75.0) | 4 (28.6) | 9 (60.0) | 29 (52.7) |
| Black | 7 (50.0) | 3 (25.0) | 9 (64.3) | 6 (40.0) | 25 (45.5) |
| Asian | 0 | 0 | 1 (7.1) | 0 | 1 (1.8) |
| Ethnicity | |||||
| Hispanic or Latino | 1 (7.1) | 4 (33.3) | 1 (7.1) | 3 (20.0) | 9 (16.4) |
| Not Hispanic or Latino | 13 (92.9) | 8 (66.7) | 13 (92.9) | 12 (80.0) | 46 (83.6) |
| Height (cm) | 162.4 ± 4.46 | 159.3 ± 5.89 | 162.9 ± 4.42 | 160.5 ± 5.80 | 161.3 ± 5.23 |
| Weight (kg) | 72.2 ± 16.55 | 72.6 ± 17.35 | 71.4 ± 20.70 | 73.9 ± 14.49 | 72.6 ± 16.90 |
| Body mass index (kg/m2) | 27.3 ± 5.52 | 28.7 ± 7.06 | 26.9 ± 7.63 | 28.7 ± 5.22 | 27.9 ± 6.27 |
Data are mean ± standard deviation or n (%).
Abbreviation: b.i.d., twice daily; q.d., once daily; VT-1161, oteseconazole.